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Glycosylation of Fmoc-hydroxyarnino acids with ~-D-glucose pentaacetate has been carried out in the presence
of several Lewis acids and BF3.Et20 has been found to be the most suitable one. Thus, 2,3,4,6-tetra-O-acetyl-~-D-
glycopyranosyl derivatives of Fmoc-Ser/Thr/Tyr are prepared in a single step in reasonably good yields and high
purity. The O-glycosylated derivatives are then converted to their corresponding trichlorophenyl esters for use in the
solid phase synthesis of five glycoopioid peptides related to dermorphin. The effect of glycosylation on biological
activity of dermorphin has been studied. Among the peptides synthesized, [Tyr(~-D-Glc)s]dermorphin and [Sertji-n-
Glc)s, Tyr7)]dermorphin exhibit considerable analgesic activity of about 80-90% compared to morphine and
antidiarrhoeal activity of about 50% compared to dermorphin.
The growing realisation of the biological
importance of glycopeptides and glycoproteins has
focussed considerable attention on their chemical
synthesis'". As direct glycosylation of peptides is
unsatisfactory, suitably protected glycosylated
amino acids are preferred in glycopeptide
synthesis. For this, the protecting groups have to be
judiciously chosen as the glycosidic bonds are
sensitive to strong acids and bases. For the
synthesis of O-glycopeptides, O-glycosylated l"?-9-
fluorenylmethoxycarbonyl (Fmoc) amino acids are
presently used. Several approaches for their
preparation and their subsequent use in the
chemical synthesis of O-linked glycopeptides have
been reported':". For the preparation of 0-
glycosylated Fmoc-amino acids, crude 3-0-
(2,3,4,6-tetra-0-acetyl-~-D-glucopyranosyl)amino
acids were first obtained by catalytic
hydrogenation of the corresponding ~-
benzyloxycarbonyl-O-glycosylated amino acid
benzyl esters followed by reaction with Fmoc-
succinimidyl carbonate 4.5. They have also been
prepared by cleavage of acid labile esters of the
l"?-Fmoc protected O-glycosylated amino acids6.
Such routes, however, are tedious and lengthy.
This paper describes a simpler procedure where 0-
glycosylation of Fmoc-hydroxyamino acids is
effected in presence of BF3.Et20 without
protection of their carboxyl group. These have
subsequently been converted to the corresponding
2,4,5-trichlorophenyl esters for use in the solid
phase synthesis of the glycoopioidpeptides related
to dermorphin.
Dermorphin (Tyr-n-Ala-Phe-Gly- Tyr-Pro-Ser-
NH2), a morphinomimetic heptapeptide isolated
from the skin of the South American frog
Phyllomedusa sauvegei exhibits high opioid
agonist activiry''". Several studies on the
synthesis, conformation and biological activity of
dermorphin and its analogues have been reported.
However, there are no reports as yet on
glycosylation of dermorphin and its effect on
biological activity. In the present studies, five
analogues of dermorphin with modifications at
positions 5 and/or 7 and glycosylation at position 1
or 5 were synthesized. In one analogue, Tyr5 was
replaced by Tyrtji-n-Glc i while in the other Tyrl
was replaced by Tyr(~-D-Glc) I residue. As
[Tyr'[dermorphin has been reported to possess
almost twice the acti vity of dermorphin II,
glycosylation in the [Tyr'[dermorphin series was
effected to obtain three analogues with either
Tyr(~-D-Glc)5, Ser(~-D-Glc)5 or Tyr(~-D-Gal)5
residue.
Different methods were tried for the preparation
of O-glycosylated hydroxyamino acids, starting
from ~-Fmoc-protected derivatives. During this
step, the carboxyl group was not protected and
glycosylation reaction was tried with ~-D-glucose
pentaacetate in presence of various metal halides
(Lewis acids)12.J3 like SnCI4, FeCh or BF3.EtzO.
Glycosylation of Fmoc-Ser was also tried with
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2,3,4,6-tetra-O-benzyl-D-glucopynmose in the
presence of trifluoromethane sulfonic anhydride".
Among them, the reaction between Fmoc-Ser
and ~-D-glucose pentaacetate in presence of
BF3.EhO was found to be the most efficient and
the resultant O-glycosylated derivative was
obtained in better yield and the purity was also
satisfactory as determined by HPLC. The reaction
appears to proceed through the formation of a
stabilized cyclic acyloxonium intermediate which
upon activation by a Lewis acid will allow
nucleophilic attack by a glycosyl acceptor to afford
anometrically pure ~-glycosideI5 (Scheme I). The
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O-glycosylated amino acids were then converted to
their corresponding trichlorophenyl esters (Scheme
II) using dicyclohexylcarbodiimide (DCC) and
trichlorophenol employing the general procedure
reported by us earlier'".
Following the same procedure, glycosylation of
Fmoc-Tyr was also carried out. In this case, the
reaction had to be carried out for a longer period
and the yield was somewhat less than that for other
hydroxyamino acids. When the same reaction was
carried out at elevated temperatures (40°, 60° and
80°), no improvement in the yield of the product
was observed. The yield and physical constants of
the glycosylated amino acid derivatives are listed
in Table 1. All the glycosylated amino acids are
fine crystals instead of the foamy solids generally
reported by others.
Alternately, Fmoc-Ser was converted to the
active trichlorophenyl ester and then glycosylation
was effected (i) with ~-D-glucose pentaacetate in
the presence of BF3.Et20 (Scheme III) , (ii) using
2, 3, 4, 6-tetra-O-acetyl-a-D-glucopyranosyi bro-
mide with Hg(CN)z and nitromethane in benzene at
80° by employing the procedure followed for the
preparation of Fmoc-Hyp[~-D-Glc(OAc)4]-OMe14.
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Fmoc - CHR - COOH
T7cpDCC BF3· E t20.s -0 -Glu-
(OAc) 5
F~:RDC:T:F3Et,O F2 :COOH
(OAc) 5 / .vt'.
Fmoc - CHR (Y) - OTcp
R = CH20H or CH (CH3) OH or CH2 C6H40H (p)
Y = 2 • 3 • 4 • 6 - tetra - 0 - acetyl -]3 - 0 - glucose I galactose
Tcp = 2 . 4 . 5 - trichlorophenol
Scheme III
also low. Thus, glycosylation of Fmoc-
hydroxyamino acid with ~-D-glucose pentaacetate
in the presence of BF3.Et20 was found to be
efficient when the a-carboxyl group is free..
The utility of these Fmoc-O-glycosylated amino
acid derivatives in solid phase peptide synthesis
has been demonstrated by the synthesis of five
analogues of dermorphin having O-glycosylated
serine or tyrosine at positions 1 or 5. The synthesis
of the protected heptapeptides on a conventional
Merrifield resin (chloromethylated polystyrene
crosslinked with 2% divinylbenzene) was
accomplished by using appropriate Fmoc-amino
acid trichlorophenyl esters in presence of 1-
hydroxybenzotriazole (HOBt)lI with suitable
modifications. For the cleavage of peptide from the
resin, direct ammonolysis (methanolic ammonia at
0° for 72 h) was not found to be appropriate
because of the characteristic base lability of the 0-
glycosidic bonds. Hence, the protected
glycopeptide amides have been obtained in a two
step process. The protected peptide was cleaved
from the solid support by KeN/methanol (MeOH)
method'" to get the free acid which was then
Table I-Analytical data of Fmoc-O-glycosylated amino acids and their trichlorophenyl esters
S1. No. Compound Yield m.p. [a]025 Revalues
(%) (0C) ReA RrB
Fmoc-Ser[Gle(OAc) 4]* 53 86-88 +20.0° 0.49 0.62
(el, CHCI3)
2 Fmoc-Ser[Gal(OAc) 4] 52 foamy solid + 16.8° 0.50 0.65
(c 1.1,CHCI3)
3 Fmoc-Thr[Gle(OAc) 4]** 50 120-121 - 17.1 ° 0.56 0.70
Fmoc- Thr[Gal(OAc) 4]*
(c 1, MeOH)
4 51 83-85 -4.6° 0.45 0.72
(c 1.12, MeOH)
5 Fmoc- Tyr[Gle(OAc) 4] 43 108-110 + 20.0° 0.73 0.88
(c 0.5 CHCI3)
6 Fmoc- Tyr[Gal(OAc) 4] 40 93-95 + 50.0° 0.52 0.71
(c I, CHCI3)
7 Fmoc-Ser[Gle(OAc)4]-OTcp 39 foamy solid +13.7° 0.43 0.73
(c I,CHCI3)
8 Fmoc-Ser[Gal(OAc)4]-OTcp 62 96-98 + 6.3° 0.78 0.86
(c 0.8, CHCI3)
9 Fmoc- Thr[Gle(OAC)4]-OTcp 60 146-148 -58.r 0.86 0.95
(c 0.9, CHCI3)
10 Fmoc-Thr[Gal(OAc)4]-OTcp 60 128-130 - 55.5" 0.88 0.91
(c 0.9, CHCI3)
II Fmoc- Tyr[ Gle( 0Ac )4]-OTcp 56 105-107 + 16.6° 0.90 0.84
(c 1.2, CHCI3)
12 Fmoc-Tyr[Gal(OAc)4]-OTcp 55 98-101 0.89 0.84
The abbreviations used for amino acids are in accordance with recommendations of lUPAC-lUP commission on Biochemical
Nomenclature published in "Pure and Applied Chemistry", 40(1974) 314. Elemental analysis of these compounds were found
to be satisfactory. * la, See Ref.7, reported: foam; [a]o +'25° (c 0.4, CHCh) ; ** Ie, See Ref. 4, reported: m.p. 126° dec ;
[a]o - 17.1 ° (c 0.61, MeOH) ; # Id, See Ref. 4, reported: m.p. 80-82° dec ; [a]o - 4.6° (c l.l2, MeOH).
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The opiate agonistic properties of the synthetic
O-glycopeptides were studied using the co-axially,
electrically stimulated contractions of the isolated
guinea pig ileum (GPO in vitro'" and in vivo
analgesic activity using Eddy's hot plate method'".
The antidiarrhoeal activity (in vivo) was
determined by the charcoal meal test based on the
inhibition of the gastrointestinal motility". The
activities were determined relative to morphine
sulphate as standard and the results are
summarised in Table II.
In the GPI assay, the synthetic analogues, except
[Tyr(G1c)I]dermorphin, exhibited 1110th the
activity of morphine; [Tyr(G1c)I]dermorphin being
almost inactive. In the analgesic assay, all the
glycosylated peptides showed considerable
activity. Glycosylation of Tyr at position 5 in
dermorphin and substitution of Tyr5 by 0-
glycosylated serine in [Tyc'[dermorphin led to
peptides 6 and 7 with considerable analgesic
activity, being respectively 0.8823 'and 0.8240
times as active as morphine. In [Tyr'jdermorphin,
glycosylation of Tyr5 by either P-D-glucopyranose
or p-D-galactopyranose unit gave peptides 8 and 9
which showed about 70% of the analgesic activity
compared to morphine. These two peptides, though
less active, are equipotent in all the assays,
indicating that substitution of glucopyranose for
galactopyranose residue, in the dermorphin series
does not have any influence on activity. Peptides 6
and 7 exhibited considerable antidiarrhoeal activity
compared to both morphine and dermorphin while
the other peptides (peptides 8, 9 and 10) were
almost inactive in this assay. Thus, peptides 8, 9
and 10 are unique in possessing only analgesic
activity to the virtual exclusion of the other two
activities. From the biological activities listed in
Table II, it is clear that the glycopeptides have
much less GPI activity as compared to morphine or
the parent compound. While the analgesic
activities are comparable or less than that of
morphine, it is much less active than dermorphin.
The antidiarrhoeal activities are also less as
compared to dermorphin. Also, there is a certain
degree of selectivity in the activities and such
peptides with high degree of specificity may prove
useful in biological applications.
Experimental Section
All the amino acids used, except glycine, are of
L-configuration unless otherwise specified.
Melting points were determined using Leitz-
Wetzlar melting point apparatus and are
uncorrected. Thin layer chromatography (TLC)
was performed on precoated silica gel G plates by
ascending method using the following solvent
systems (A) chloroform-methanol-acetic acid
(40:2: 1, v/v/v), (B) ethyl acetate-hexane-acetic acid
(80:17:3, v/v/v), (C) n-butanol-acetic acid-water
(4:1:1, v/v/v, upper phase) and (D) n-butanol-
acetic acid-water (4:1:5, v/v/v, upper phase) and
the R, values are designated as RrA, R, B, R, C and
R, D respectively. Analytical HPLC was performed
on Waters LC 3000 system equipped with Waters
Table ll-Biological activity of synthetic O-glycopeptides related to dermorphin
Peptide GPI Analgesic
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484 tunable absorbance UV detector and a
Millipore 745 data module. Waters RP C18-
deltapak. column (3.9 rnrn x 30 em, 15 u, spherical)
was used for analysis. Optical rotations were
recorded using automatic digital AA-I0
polarimeter (Optical Activity, UK). Amino acid
analyses were carried out using Waters PICO-TAG
system. For elemental analysis, amino acid
derivatives dried over P20S under vacuum for 24 h
were used. PMR spectra were determined on
Brucker ACF instrument. The coupling and
deprotection reactions, during the course of the
synthesis, were monitored by Kaiser's ninhydrin
test22. Fmoc-amino acids and their 2,4,5-
trichlorophenyl esters were prepared by following
the reported procedures'". However, Fmoc-
SerfThr-OTcp whose preparation was reported to
be difficult'", have now been prepared in a
crystalline form and employed during the present
investigations.
Fmoe-Serffhr-OTep: Fmoc-SerfThr (10
rnrnole) and 2, 4, 5-trichl'orophenol (10 rnrnole)
were dissolved in dry ethyl acetate (25 rnL) and the
solution was cooled to 0°. Then OCC (12 rnrnole)
was added and the mixture was stirred for 4 h at 0°
and overnight at room temperature. The mixture
was cooled to - 10° and insoluble dicyclohexylurea
(OCU) was filtered off. The filtrate was washed
with H20, 5% NaHC03 solution, H20 and
saturated NaCI solution. It was then dried over
Na2S04 and concentrated in vacuo. The residue
was recrystallised from ethyl acetate-hexane.
Fmoc-Ser-OTcp: Yield 68%; m.p. 118-20°; ReA
0.53; [a]D2S-20.3° (c 1, CHCh) (Calc. for
C24HI8NOsCI3: C, 56.86; H, 3.55; N, 2.76. Found:
C, 56.91; H, 3.59 N, 2.80); HPLC: tR 18.51 min
(elution: isocratic 35% aq. acetonitrile containing
0.1 % TF A at a flow rate of 1 rnL/min and UV
monitoring at 220 nrn); 'H NMR (400 MHz,
COCh): 4.00-4.15 (m, 2H, Ser ~-H2)' 4.26 (t, IH,
Fmoc-CH), 4.43 (d, 2H, Fmoc-CH2), 5.66 (bd, IH,
NH), 7.23-7.88 (m, IOH, ArH). Fmoc-Thr-OTcp:
Yield 65%; m.p. 106-108°; RrA 0.58; [a]D2S-26.8°
(c I, CHCI3) (Calc. for C2sH20NOsCh: C, 57.63; H,
3.94; N, 2.69. Found: C, 57.68; H, 3.96; N, 2.71);
HPLC: tR 17.53 min (elution: isocratic 35% aq.
acetonitrile containing 0.1 % TFA at a flow rate of
1 rnL/min and UV monitoring at 220 nm); 'H
NMR (400 MHz, CDCh): 1.45 (d, 3H, Thr y-H),
4.25 (rn, IH, Fmoc-CH), 4.43 (dq, IH, Thr ~-H),
4.56 (d, 2H, Fmoc-CH2), 4.75 (dd, IH, Thr a-H),
5.80 (d, IH, Thr-NH), 7.30-7.81 (m, 1OH, ArH).
Fmoc-O-(tetra-O-aeetyl-~-D-glueopyranosyl)-
Ser la. To a solution of Fmoc-Ser (2.71 g, 8.28
rnrnole) and ~-D-glucose pentaacetate (3.32 g, 8.5
rnrnole) in dry acetonitrile (10 mL) at room
temperature was added boron trifluoroetherate
(2.61 rnL, 20.7 rnrnole). After 2-3 h (reaction
monitored by TLC), the reaction mixture was
diluted with CH2Ch (30 rnL) and washed with 1M
HCI (2xlO rnL). The aq. layer was then extracted
with CH2Ch (2x1O rnL). The organic layers were
pooled, washed with water, dried over anhyd.
Na2S04 and evaporated. The gum obtained was
subjected to column chromatography over silica
gel using ethyl acetate-hexane-acetic acid (18:17:3,
v/v/v) as eluant. The fractions corresponding to the
product were pooled, concentrated and
recrystallised from CH2Clrhexane. The final
purity was established by arialytical HPLC (Figure
la). IH NMR (300 MHz, acetone-sa): 1.97, 1.99,
2.01 and 2.03 (4s, 3H each, Ac), 3.79 (dd, IH, H-
~), 4.07 (dd, IH, H-6), 4.39 (m, IH, H-a), 4.89 (d,
IH, H-I), 4.93 (dd, IH, H-2), 5.03 (t, lH, H-4),
5.28 (t, IH, B-3), 6.54 (d, IH, NH), 7.20 - 7.74 (rn,
8H, ArH).
By following the same procedure, Fmoc-O-
(tetra-O-acetyl-~-D-galactopyranosyl)Ser lb and
Fmoc-O-tetra-O- acetyl-Beu-gluco/galactopyrano-
syl)Thr le/ld were prepared. The yields and
physical data are listed in Table 1.
Fmoe-O-( tetra-O-aeetyl-~-D-glueopyranosyl)-
Tyr Ie. To a mixture of Fmoc-Tyr (2.01 g, 5
rnrnole) and ~-D-glucose pentaacetate (3.9 g, 10
rnrnole) in dry acetonitrile (6 rnL) was added boron
trifluoroetherate (1.62 rnL, 12.5 rnrnole) and stirred
at room temperature overnight. The reaction
mixture was then diluted with CH2Ch (30 rnL) and
washed with water (3 x 10 rnL). The organic layer
was dried over anhyd. Na2S04 and concentrated in
vacuo. The gum obtained was purified by flash
chromatography over silica gel G using ethyl
acetate - hexane (6:4, v/v) as eluant and the
product was recrystallised from ethyl acetate-
hexane. The purity of the compound was' checked
by analytical HPLC (Figure n». 'H NMR (300
MHz, acetone-ox) 1.97, 1.99,2.00 and 2.02 (4s, 3H
each, Ac), 2.98 (dd, IH, H-~), 3.23 (dd, IH, H-~),
4.49 (m, 1 H, H-a), 5.08 (t, IH, H-4), 5.14 (dd, IH,



















Figure Ia-Elution profile of pure Fmoc-O-(tetra-O-acetyl-13-
D-glucopyranosyI)Ser. Elution: isocratic 35% aq. acetonitrile
containing 0.1 % TFA at a flow rate of I mUmin and UV
monitoring at 220 nrn; (b) Elution profile of pure Fmoc-O-
(tetra-O-acetyl-13-D-glucopyra~osyl)Tyr. Elution: isocratic
35% aq. acetonitrile containing 0.1 % TFA at a flow rate of I
mUmin and UV monitoring at 220 nm; (c) Elution profile of
pure Fmoc-O-(tetra-O-acetyl-13-D-glucopyranosyl)Tyr-OTcp.
Elution: isocratic 35% aq. acetonitrile containing 0.1 % TFA at
a flow rate of I mUmin and UV monitoring at 220 nm; (d)
Analytical RP-HPLC profile of [Tyr(13-D"Glc)5]dermorphin.
Eluant A, aq. 0.1 % TFA; eluant B, 0.1 % TFA in acetonitrile.
Flow rate I mUmin; UV monitoring at 220 nm. Elution: linear
gradient of 25-1 00% 8 over 30-min.
H-2), 5.24 (d, IH, H-l), 5.34 (t, IH, H-3), 6.74 (d,
,IH, NH), 6.98 - 7.28 (2d, 4H, Tyr E, 8-H).
Fmoc-O-(tetra-O-acetyl-~-D-GIc/Gal)Ser/-
Thr/Tyr-O'I'cp (2a-O: To a well stirred solution of
Fmoc-O-(tetra-O-acetyl-~-D-Glc/Gal)Ser/Thr/-Tyr
(10 mmole) and 2, 4, 5-trichlorophenol (11 mrnole)
in dry ethyl acetate (35 mL) cooled in an ice bath
was added DeC (11 mmole) and stirring continued
for 2 h and at room temperature for 2 h. The
separated DCU was filtered off and the filtrate
concentrated in vacuo. The product was recry-
stallised from ethyl acetate-hexane. The yields and
physical constants are listed in Table 1. The purity
of the compounds were found to be >98% by
HPLC (Figure l c),
Peptide synthesis
Synthesis of [Tyr (~-D-GIc)5 ]dermorphin
Boc-Ser-Of'Hj-Czfla-resln. A mixture of Boc-
Ser (5 mrnole), Merrifield resin (3.0 g), absolute
ethanol (12 mL) and NEt3 (6 mrnole) was stirred at
90° for 24 hr under anhyd. conditions. The
esterified resin was collected and washed
successively with ethanol, water, ethanol, CH2Ch
and methanol and dried over P205 in vacuo, yield
3.42 g. The Ser content on the resin was estimated
to be 0.39 mrnole/g by the Volhard method".
Boc- Tyr-D-Ala-Phe-Gly- Tyr[~-D-GIc(OAc)4]-
Pro-Ser-OCH2-C6H4-resin 3. Boc-Ser-OCHz-
C6H4-resin (1.7 g) was taken in a solid phase vessel
and synthesis continued manually using
appropriate Fmoc-amino acid trichlorophenyl
esters in the presence of l-hydroxybenzotriazole as
reported earlier" with suitable modifications.
Cleavage of Frnoc group was effected by using
60% diethylamine in dimethylformamide (DMF).
However, after the coupling of glycosylated amino
acid residue: cieavage of Fmoc group was
accomplished with 50% piperidine in DMF.
The chain elongation was then carried out by
stepwise addition of Fmoc-Pro-OTcp (1.06 g, 3
equiv.), Fmoc-Tyr[~-D-Glc(OAc)4]OTcp (1.85 g, 3
equiv.), Fmoc-Gly-OTcp (0.98 g, 3 equiv.), Fmoc-
Phe-OTcp (1.16 g, 3 equiv.), Fmoc-D-Ala-OTcp
(1.00 g, 3 equiv.) and Boc-Tyr-O'I'cp (0.95 g, 3
equiv.) in the presence of HOBt (0.089 g, 1 equiv.)
in DMF. The reaction time for coupling of each
amino acid was generally ()O-120 min except for
glycosylated amino acid which took 160-180 min.
After each coupling, the resin was washed with
DMF (3 x 2 min), isopropanol (3x2 min), CH2Ch
(3x2 min) and ether (3x2 min).: After the
completion of the synthesis, the protected peptide
resin was dried in vacuo over P205 and KOH.
Yield, 2.32 g.
Boc-Tyr-D-Ala- Phe-Gly- Tyrtjl-n-Glcj-Pro-
Ser 4. The protected peptide resin (3, 2.0 g) was
stirred with KCN (200 mg/g) and 95% aq.
methanol (30 mLlg) at room temperature for 24
hr'7. The solution was neutralized with IN HCl.
Resin was filtered and washed with hot methanol.
The combined filtrate and washings were
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concentrated to dryness in vacuo. To this was
added 8-10 mL of distilled water and brought the
pH to 2 using IN HCl. White precipitate separates
out which was extracted with ethyl acetate three
times. The organic layers were pooled, washed
with water and dried over Na2S04. The protected
peptide obtained, after concentration in vacuo, was
crystallised from methanol-ether, yield, 0.342 g
(68% based on the extent of Ser esterified to the
resin).
Boc- Tyr-D-Ala-Phe-Gly- Tyr(~-D-Glc)-Pro-
Ser-NHz 5. The protected peptide (4, 0.212 g, 0.2
mmole) was dissolved inDMF (1.0 mL) and HOBt
(0.044 g, 0.33 mmole) and DCC (0.04 g, 0.21
mmole) were addedl8. The mixture was stirred for
30 min. Then 25% aq. ammonia (0.05 mL, 0.65
mmole) was added at 00, and stirring continued for
2 .hr at 0° and overnight at room temperature
(reaction monitored by TLC). The insoluble by-
products were filtered off and the filtrate was
diluted with CH2Ch (10 mL). This solution was
washed with 2% NaHCO, solution (3 x 5 ml.),
water (5 mL), 5% citric acid (2x3 mL) and water 4
(5 mL), dried over anhyd. Na2S04 and evaporated
in vacuo to give the protected peptide amide which
was recrystallised from methanol-ether (1 :3), yield,
0.16 g (73%). .
Try-D-Ala-Phe-Gly-Tyr(~-D-Glc)-Pro-Ser-
NH2 6. The protected peptide amide (5, 0.098 g, 1
mmole) was treated with TFA: CH2Ch (1: 1) for 1
hr (reaction monitored by TLC). After complete
deprotection of Boc group, the reaction mixture
was concentrated in vacuo and concentration
repeated twice by addition of MeOH. The resulting
gum was then dissolved in ethyl acetate and
neutralized with 2% NaHCO, solution to get the
free peptide amide. The crude peptide was purified
on a silica gel column (30 em x 2 em) using ethyl
acetate-hexane-acetic acid (90: 10: 1, v/v/v) as
eluant. The purity of final peptide was checked by
analytical RP-HPLC (Figure Id), yield, 0.056 g
(66%); m.p. 110-12°; Rf C 0.74; Rf D 0.65; amino
acid analysis: Ser (1) 1.04, Tyr (2) 1.96, Gly (1)
0.98, Phe (1) 1.01, Ala (1) 0.97.
By following the same proforma and with
appropriate modifications where necessary, the
remaining four glycopeptides related to
dermorphin 7 to 10 were obtained. The yields and
physical data are listed in Table Ill.
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